These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player]. Pukoli D; Vécsei L Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344 [TBL] [Abstract][Full Text] [Related]
4. B cell-directed therapies in multiple sclerosis. Gasperi C; Stüve O; Hemmer B Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316 [TBL] [Abstract][Full Text] [Related]
5. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. Frisch ES; Pretzsch R; Weber MS Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738 [TBL] [Abstract][Full Text] [Related]
7. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Ancau M; Berthele A; Hemmer B Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436 [TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab for the treatment of multiple sclerosis. Bigaut K; De Seze J; Collongues N Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368 [TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R Front Immunol; 2023; 14():1004795. PubMed ID: 37033984 [TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986 [TBL] [Abstract][Full Text] [Related]
11. Therapies for multiple sclerosis targeting B cells. Milo R Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580 [TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab: its efficacy and safety in multiple sclerosis. Juanatey A; Blanco-Garcia L; Tellez N Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610 [TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. Sellebjerg F; Blinkenberg M; Sorensen PS CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023 [TBL] [Abstract][Full Text] [Related]
16. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283 [TBL] [Abstract][Full Text] [Related]
17. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. Gasperini C; Haggiag S; Ruggieri S Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792 [TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab: A Review in Multiple Sclerosis. Lamb YN Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158 [TBL] [Abstract][Full Text] [Related]
19. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Pers YM; Jorgensen C Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081 [TBL] [Abstract][Full Text] [Related]
20. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]